NCT02159222

Brief Summary

The purpose of this study is to determine whether an additional physical therapy program can improve the mobility and functional outcomes of patients diagnosed with severe sepsis (an illness in which the body has a severe response to bacteria or other germs and develops worsened function of a major organ such as the kidneys, heart, or lungs).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable sepsis

Timeline
Completed

Started Apr 2014

Longer than P75 for not_applicable sepsis

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 22, 2014

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 9, 2014

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

October 16, 2019

Status Verified

October 1, 2019

Enrollment Period

5.4 years

First QC Date

May 22, 2014

Last Update Submit

October 14, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline ambulation

    Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days. This outcome will be assessed at baseline and at each study protocol physical therapy session during the index hospitalization.

    At day 0 (baseline enrollment) and for the duration of the participants' hospitalization, a predicted average length of stay of 5 days.

Secondary Outcomes (6)

  • Change in Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (iADLs)

    At day 0 (baseline enrollment) and day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days)

  • Discharge location

    At day 5 (assessed at discharge; predicted average length of stay is 5 days)

  • ICU Transfer Rate

    Participants will be followed for the duration of their hospitalization, an average length of stay of 5 days.

  • Length of stay

    Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.

  • Employment status

    At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).

  • +1 more secondary outcomes

Other Outcomes (8)

  • Readmission

    At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).

  • In-Hospital Mortality

    Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days

  • Falls

    Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.

  • +5 more other outcomes

Study Arms (1)

Additional physical therapy

EXPERIMENTAL
Procedure: Additional physical therapy

Interventions

Additional physical therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Any English-speaking patient over the age of 18 who is currently admitted to a general care floor under the care of the Medicine Faculty Hospitalist Service at the University of Michigan Health System and has severe sepsis is eligible to take part in this study.

You may not qualify if:

  • Subjects must be deemed by the study team to give informed consent by being able to state the basic purpose of the study. Consent by a legally authorized representative (LAR) will not be sought.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48105, United States

Location

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Andrew Odden, MD

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Internal Medicine, Medical School

Study Record Dates

First Submitted

May 22, 2014

First Posted

June 9, 2014

Study Start

April 1, 2014

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

October 16, 2019

Record last verified: 2019-10

Locations